European Cancer Organisation



Openness and Transparency is a core value of our organisation – ECCO is committed to be transparent in and accountable for all it does.

ECCO in the EU Transparency Register

The EU transparency register has been set up to answer core questions such as what interests are being pursued, by whom and with what budgets.  As an influential not-for-profit organisation based in Brussels and actively involved with the European institutions on matters of public health, ECCO is present in the EU Transparency Register and regularly updates its information in it.  It can be viewed under identification number 51022176260-12 or by clicking on this link:

BioMed Alliance Code of Conduct

ECCO is a founding member of the Alliance for Biomedical Research in Europe (BioMed Alliance), together with the European Association for the Study of Diabetes (EASD), European Respiratory Society (ERS) and the European Society of Cardiology (ESC).

The BioMed Alliance aims at promoting the best interests and values of research across all medical disciplines in Europe, in those general areas where common interest is identified.

As a member of the BioMed Alliance, ECCO has adopted its Code of Conduct which sets out core principles to maintain and enhance professional independence, objectivity and scientific integrity.

The BioMed Alliance Code of Conduct also helps to ensure that the Alliance’s interactions and collaborations with the healthcare sector are for the benefit of patients and for the improvement of scientific standards and medical care.

The BioMed Alliance Code of Conduct oversees aspects of healthcare professionals and healthcare organisations’ relationship with industry and stakeholders. These include continuous medical education, professional development, scientific meetings, exhibition at congresses and research funding.

The BioMed Alliance Code of Conduct sets high ethical standards and responds to the evolving demands of society.

For the full text of the BioMed Code of Conduct, click here.

EFPIA Disclosure Code

The ‘EFPIA Code on Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’ ( EFPIA Disclosure Code) is a set of self-regulatory industry transparency standards for pharmaceutical companies operating in 33 European countries.

It requires EFPIA member companies and members of EFPIA member associations to publicly disclose payments and other transfers of value made to healthcare professionals (HCPs) and healthcare organisations (HCOs) in certain categories. For example, this could include grants given to HCOs, or consultancy fees for HCP speaking engagements.

The first reporting period is 1 January – 31 December 2015. The first public disclosure has been made in 2016, retrospectively for the year 2015.

Since ECCO is established in Belgium, disclosure data for our organisation is published on

How is ECCO using the funds it has received in 2015 from conferences and other sources?

Some of the income generated by ECCO in 2015 is used to provide grants to ECCO member societies so that they can implement their own core activities in oncology.  Such activities include (but are not limited) to essential continuing medical education of societies’ individual members (healthcare professionals), cancer research related activities, policy efforts on behalf of cancer patients, design of clinical guidelines and others.  The income which remains with ECCO is used to sustain the organisation’s core activities designed and implemented by its Board and Executive Office in order to deliver ECCO’s vision of improving outcomes for all cancer patients in Europe through multidisciplinarity.

It covers staff costs, general administrative and operational costs (e.g. office rent, essential travel), design and implementation of oncopolicy and quality cancer care activities, participation in relevant EU initiatives, cooperation with patient organisations, communication, organisation of the ECCO European Cancer Congress.

PRINT THIS PAGE Page last modified: